Why Cannabis Biotech Needs to be in Your Portfolio Right Now

Why Cannabis Biotech Needs To Be In Your Portfolio Right Now

The biotech sector may be one of the biggest beneficiaries of the legal cannabis movement. In previous articles, we have been quite vocal about our bullish stance on the cannabis biotech sector. In the current US markets, we believe the greatest opportunity lies in biotech and the pharmaceutical production of cannabinoid and cannabis related drug treatments. And recent political shifts may have just created a perfect storm for cannabis biotech investors. Right now could be your greatest opportunity to consider adding cannabis biotech to your portfolio. And we aren’t the only ones who think so. Todd Hagopian, manager of a biotech fund at Marketocracy, believes the biotech sector will benefit most from a Donald Trump Presidency. Todd is one of the most successful biotech investors in the market today. His returns haveaveraged 26.03% since starting his fund in 2011, which compares nicely to the S&P 500’s 11.58% return over the same period.Over the last five and three year periods,...

See Article on Marijuana Stocks HERE